BioAI, an emerging biotech company applying multimodal artificial intelligence (AI) to novel biomarker discovery, development, and diagnostics, announced a strategic collaboration with Genomic Testing Cooperative (GTC), a leading provider of molecular diagnostics for solid tumors and hematologic malignancies. This collaboration leverages the AI capabilities of both companies to deliver innovative solutions that meet the needs of pharmaceutical companies and clinicians, ultimately enhancing patient care in oncology. GTC will become an early technology access member of BioAI’s global ecosystem of clinical laboratories.
Goals of the collaboration include:
- Data Access and AI Training: GTC will provide BioAI with access to characterized imaging data to train AI algorithms for product development and sponsored projects.
- Biomarker Development: Joint efforts will focus on developing genomic biomarker screening algorithms and assays, deploying them in clinical settings.
- Comprehensive Solutions: Customers will benefit from a suite of solutions encompassing screening tests and comprehensive genomic profiling using DNA and RNA for tissue and liquid biopsies.
Also Read: BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed Into Portfolio
Thomas Colarusso, CEO of BioAI, stated: “BioAI is excited to partner with leaders in clinical laboratory services and diagnostics such as GTC to support the development, validation and future deployment of novel AI-based tests. GTC is a perfect partner for us since they have a strong track record of developing and launching new clinical biomarker tests for primary care and supporting biopharma research and clinical trials to improve patient care and drive therapy decisions.”
Jeff Owen, Vice President, Marketing, stated: “GTC is delighted to partner with BioAI, their digital pathology technology strengthens our product portfolio to pharmaceutical clients and will help us to demonstrate the potential of our digital and molecular sample bank in the development of clinically useful comprehensive biomarkers. We recognize that AI algorithms in digital pathology when combined with molecular profiling advance our capability of developing biomarkers that can be used by all pathologists.”
Source: Genomic Testing
